Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02097238
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
NIH
Sponsor class
Conditions
Recurrent Osteosarcoma
Interventions
DRUG:
Eribulin Mesylate
OTHER:
Pharmacological Study
Sponsor
National Cancer Institute (NCI)